Editorial Board ::: Current Pharmaceutical Design

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)


Volume 23, 46 Issues, 2017


Download PDF Flyer




Current Pharmaceutical Design

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 73rd of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
William A. Banks
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.052
5 - Year: 3.132

Editorial Board

Editor-in-Chief:

William A. Banks (Biography
William A. Banks

Dr. Banks obtained his MD from the University of Missouri- Columbia and did clinical and research training at the Veterans Affairs Medical Center – New Orleans and Tulane University. He is currently Associate Chief of Staff –Research and Development at the Puget Sound VA and Professor of Medicine at University of Washington School of Medicine. His main interest is in blood-brain barrier function. He has published over 450 non-abstract articles, and over 20,000 citations according to Web of Science with an H-index fo 81.

)

VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA



Regional Editor(s):

Region: Asia
Seiji Shioda (Biography
Seiji Shioda

Dr. Seiji Shioda obtained a doctorate (Ph.D) in Medical Science in Showa University School of Medicine, Tokyo. Currently Dr. Shioda is professor of Hoshi University, Global Research Center for Innovative Science (GRIL), Peptides Drug Innovation. Dr. Shioda is also an Adjunct Professor of Tulane University Medical School. He has published more than 500 scientific publications and is a named inventor of 10 issued Japanese patents. Dr. Shioda has been the Regional Editor (Asia) of Current Pharmaceutical Design, published by Bentham Science Publishers.

)

Hoshi University
Tokyo
Japan
Region: Europe
Dimitri Mikhailidis (Biography
Dimitri Mikhailidis

Dimitri Mikhailidis graduated from the University of London (BSc, MSc, MB,BS and MD) and is Academic Head, Department of Clinical Biochemistry, Royal Free Hospital campus, University College London Medical School. He is also a Visiting Professor, Univ. of Belgrade, Serbia and at two universities in Saudi Arabia. His research interests are dyslipidaemias and thrombosis.

He is a Fellow of the Royal College of Pathologists (FRCPath), Royal College of Physicians (FRCP), Faculty of Pharmaceutical Medicine (FFPM) and American College of Clinical Pharmacology (FCP). He has 22,118 citations on the ISI index, Core Collection (H-factor 64).

)

Royal Free Hospital
London
UK

Section Editor(s):

(HIV Agents)
Howard Gendelman (Biography
Howard Gendelman

Dr. Howard E. Gendelman is the Margaret R. Larson Professor of Internal Medicine and Infectious Diseases and Chairman of the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center. He is credited in unraveling how functional alterations in brain immunity induce metabolic changes and ultimately lead to neural cell damage for a broad range of infectious and neurodegenerative disorders. These discoveries have led to novel therapeutics aimed at reversing neural maladies. He obtained a Bachelor’s degree in Natural Sciences and Russian Studies from Muhlenberg College and his M.D. from the Pennsylvania State University where he was the 1999 Distinguished Alumnus.

)

University of Nebraska Med. Ctr
Omaha, NE
USA

(Nanotechnology)
Alexander V. Kabanov
University of North Carolina at Chapel Hill
Chapel Hill, NC
USA

(Anti-hypertensive Agents)
Gregory Lip
City Hospital
Birmingham
UK

(Computer Assisted Drug Design)
Rami Reddy (Biography
Rami Reddy

Dr. Reddy obtained a doctorate (Ph. D.) in Computational Chemistry from the Central University of Hyderabad, Hyderabad, India. Dr. Reddy is a founder of Rational Labs and is highly accomplished computational Chemist with a proven track record in drug discovery and CADD software development. Dr. Reddy has over 25 years of experience in drug discovery working in several Pharmaceutical and Biotech companies such as Agouron Pharmaceuticals (now Pfizer), Gensia Pharmaceuticals, Metabasis Therapeutics and Rational Labs. Dr. Reddy’s drug discovery efforts have resulted in one marketed drug for AIDS and several clinical compounds for cancer and diabetes. Dr. Reddy is an author of over 100 publications and patents.

)

RR Labs Inc
San Diego, CA
USA

(Immune Agents)
Emilio Jirillo (Biography
Emilio Jirillo

Emilio Jirillo is full professor of Immunology at University of Bari Medical School (Bari, Italy) since 1986.His current fields of interest are: mucosal immunity, microbial immunity and immunonutrition.Especially in this last field, he has recently published in vitro and in vivo studies on the anti inflammatory effects of polyphenols . He is author of more than 560 papers(326 scientific papers are listed in PUBMED), even including books and chapters of books. He is editor-in-chief- of the following Bentham journals:1. Endocrine Metabolic Immune Disorders-Drug Targets ; 2.Clinical Immunology Endocrine Metabolic Drugs.

)

Bari University
Bari
Italy

(Endocrine and Metabolic Agents)
Abba Kastin (Biography
Abba Kastin

Abba J. Kastin was born in Ohio and educated at Harvard College and Harvard Medical School. After starting his work on neuropeptides as a Clinical Associate at NIH, he went to Louisiana where he now holds an endowed chair at the Pennington Biomedical Research Center. In recognition of the concepts he introduced into the field of biologically active peptides, Dr. Kastin has been made an honorary member of 9 foreign medical societies, has received 2 honorary professorships and 3 honorary doctorates (the last one from Uppsala University), and has won several national and international awards. Author of more than 900 papers cited more than 34,500 times (H index 87), he has been listed among the 100 researchers most cited in the scientific literature. He is president of The International Neuropeptide Society/Society for Biologically Active Peptides and was founding Editor-in-Chief of the international journal Peptides for 35 years.

)

Pennington Biomed. Res. Ctr., Baton Rouge
LA
USA

(Cardiovascular/Hematologic Agents)
Dimitri Mikhailidis
Royal Free Hospital
London
UK


Editorial Board Members:

Vasilios G. Athyros
Aristotelian University, Medical School
Thessaloniki
Greece

Steven J. Brickner
University of New South Wales
Groton, CT
USA

Stevan W. Djuric (Biography
Stevan W. Djuric

Dr. Djuric received a doctorate (PhD) in chemistry from the University of Leeds (UK) followed by a postdoctoral fellowship with Professor Philip D Magnus at the Ohio State University. He holds an Adjunct Professorship in the Department of Medicinal Chemistry at the University of Kansas. He is head of the global AbbVie Medicinal Chemistry Leadership team and is also responsible for the Discovery Chemistry and Technology organization within their Discovery organization He has over 180 scientific publications, presentations and patents. He has given over 30 invited lectures at universities and national meetings. He is a member of several Editorial Advisory Boards including the journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters and Current Pharmaceutical Design.

)

Abbott Laboratories
Abbott Park, IL
USA

Nigel H. Greig (Biography
Nigel H. Greig

Nigel H. Greig (Ph.D. Pharmacology, University of London, England) heads the Drug Design & Development Section within the Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health. Located in Baltimore, MD, USA, his program combines cellular, molecular and in vivo pharmacology with medicinal chemistry to design and development novel experimental drugs against rate-limiting steps involved in the pathophysiology of diseases associated with aging, with an emphasis on the nervous system. Nigel, together with his exceptional collaborators and research group have successfully moved multiple experimental drugs from concept through preclinical studies and into human clinical trials.

)

National Institutes of Health
Baltimore, MD
USA

Keith W. Kelley (Biography
Keith W. Kelley

Keith W. Kelley is a Professor Emeritus of Immunophysiology at the University of Illinois. Dr. Kelley earned his Ph.D. in 1976, a time when the immune system was considered only to protect against infectious diseases. He helped reshape that view by bringing physiology to immunology. It is now accepted that there is an active dialogue between the immune system and brain, and these discoveries are improving human and animal health. Professor Kelley has been honored with 10 university and national awards, published more than 250 peer-reviewed scientific papers as well as 70 book chapters, is well cited with an h-index of 68, been funded for 50 years as the Principal Investigator of NIH grants and served on four dozen NIH study sections. He is currently a Full Member of the Neuroendocrinology, Neuroimmunology, Rhythms and Sleep Study Section. Dr. Kelley is a Past-President and Secretary-Treasurer of the PsychoNeuroImmunology Research Society. He has been Editor-in-Chief of Brain, Behavior, and Immunity since 2003. The latest impact factor of the journal is 5.9, ranking it in the top 14% of all immunology journals and 11% of neuroscience journals.

)

University of Illinois
IL
USA

JoEllyn McMillan (Biography
JoEllyn McMillan

Dr. McMillan earned a Ph.D. in Toxicology from Texas A&M University, College Station, TX, USA. She held a post-doctoral fellowship at the National Center for Toxicological Research, Jefferson AR, USA, and a second post-doctoral fellowship in the Department of Pharmacology and Experimental Therapeutics, College of Medicine, at the Medical University of South Carolina, Charleston SC, USA. She remained at the Medical University of South Carolina as an Assistant Professor in the Pharmacology Department and then moved to the University of Nebraska Medical Center, Omaha, NE, USA, in 2007. She holds a joint appointment in the Department of Pharmacology and Experimental Neuroscience, College of Medicine, and the Department of Environmental, Agricultural and Occupational Health, College of Public Health. She has authored/coauthored over 70 scientific publications and book chapters.

)

University of Nebraska Medical Center
Omaha, NE
USA

Ruth Nussinov (Biography
Ruth Nussinov

Ruth Nussinov graduated from Rutgers, was in the Weizmann Institute, the Chemistry Department at Berkeley and Biochemistry at Harvard. She joined the Medical School in Tel Aviv and accepted a concurrent position at the National Cancer Institute, Leidos. She has co-authored over 550 papers. She is the Editor-in-Chief in PLoS Computational Biology, and an Associate Editor and on the Editorial Boards of several journals. She is a frequent speaker in Domestic and International meetings, symposia and academic institutions, won several awards and elected fellow of several societies. Her National Cancer Institute website describes her science, and major contributions. https://ccr.cancer.gov/ruth-nussinov.

)

National Cancer Institute
Frederick, MD
USA

Matteo Antonio Russo (Biography
Matteo Antonio Russo

Prof. Matteo A. Russo obtained his Medical Degree from Catholic University Medical School in Rome (Italy). He specialized in Oncology, General Pathology (from University of Rome Sapienza) and Cardiology (Catholic University Medical School). Soon after he got a track tenure at University of Rome Sapienza Medical School, first, as Associate Professor of Experimental Oncology and then as Full Professor of General Pathology. At present, he is the Head of Basic Research and Laboratories at San Raffaele Scientific Institute; he is also President of MEBIC (Medical and Experimental Bioimaging Center, a joint consortium between San Raffaele University and University of Rome Tor Vergata). He has published more than 150 scientific papers, being awarded by three international prizes for Basic Research. Prof. Russo is member of the editorial board of 6 peer-reviewed journals.

)

IRCCS Foundation Rome, Molecular and Cell Biology Laboratory
Rome
Italy

Claudiu T. Supuran (Biography
Claudiu T. Supuran

is professor of medicinal chemistry at the Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, University of Florence, Italy. He has published more than 1250 papers, his Hirsch factor is h = 110; the number of citations since 1995 > 49800. His main research interest is on enzyme inhibitors, and especially carbonic anhydrase inhibitors, of which he discovered several new classes in the last years. One of the sulfonamides discovered in his group entered Phase I clinical trials in 2014 for the treatment of advanced, metastatic solid tumors. He is Editor-in-Chief of Expert Opinion on Therapeutic Patents, Journal of Enzyme Inhibition and Medicinal Chemistry, Current Enzyme Inhibition, etc. For the last 25 years the main interest of his research was focused on metallo-enzymes and their modulators of activity. In 2013 he was rated as the most cited scientists in Pharmacology & Toxicology by LabTimes (LabTimes 2013, 5, 38).

)

Universita degli Studi di Firenze
Florence
Italy

Xiaojun Yao (Biography
Xiaojun Yao

Xiaojun Yao received his Ph.D. degree in chemoinformatics and theoretical chemistry from University Paris 7-Denis Diderot, Paris, France, in 2004. He works as a Professor of chemoinformatics and analytical chemistry in College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China. His current research interests include computer-aided molecular design, bioinformatics, and computational biology.

)

Lanzhou University
Lanzhou
China

Scott A. Biller
Novartis Institutes for BioMedical Research
Cambridge, MA
USA

Allan Butterfield (Biography
Allan Butterfield

Dr. Butterfield earned his Ph.D. at Duke University in physical chemistry followed by a NIH Postdoctoral Fellowship in neuroscience at the Duke University School of Medicine. In 1975, Dr. Butterfield joined the faculty of Chemistry at the University of Kentucky and rose to Full Professor in 1983. Prof. Butterfield is the UK Alumni Association Endowed Professor of Biological Chemistry and Associate Vice President for Research at UK. He is a faculty member of the Sanders-Brown Center on Aging. Prof. Butterfield has over 620 refereed scientific publications, mostly on oxidative stress in brain in subjects with Alzheimer disease and its earlier stages. Dr. Butterfield pioneered the field of redox proteomics, by which oxidatively modified proteins can be identified. He has edited five books, and published over 150 abstracts, most of which were refereed. His work has been continuously funded at the University of Kentucky by federal grants from NIH, NSF, and DoD as well as foundation grants. He has trained over 60 Ph.D and M.S. students and over 25 postdoctoral scholars and visiting scientists. He has received a Presidential Award for Excellence in Science Mentoring from President Clinton at the White House, and an Honorary Doctor of Science Degree from his undergraduate alma mater, the University of Maine. Prof. Butterfield was named the 39th most cited and influential researcher on Alzheimer disease in the world as cited in the Journal of Alzheimers Disease. He is on the editorial boards of 14 journals, including Current Pharmaceutical Design.

)

University of Kentucky
Lexington, KY
USA

Roland E. Dolle
Pharmacopeia, Inc
Princeton, NJ
USA

James M. Hamby
Parke-Davis, Pharm. Res
Ann Arbor, MI
USA

Marlys Koschinsky
Queen's University
Kingston
Canada

John E. Morley (Biography
John E. Morley

John E. Morley, MB, BCh, is the Dammert Professor of Gerontology, Director, Division of Geriatric Medicine and Director of the Division of Endocrinology at Saint Louis University School of Medicine. He serves as Medical Director for two nursing homes. Dr. Morley earned a medical degree at the University of Witwatersrand in Johannesburg, South Africa. He is board certified in Internal Medicine, Endocrinology and Geriatric Medicine. He has edited over 20 books, and published more than 1300 manuscripts. He has an h-factor of 107. He serves as Editor of Journal of the American Medical Directors Association, impact factor 6.61.

)

St. Louis University Health Sciences Center
St. Louis, MO
USA

Waldemar Priebe
University of Texas
Houston, TX
USA

Andrew V. Schally (Biography
Andrew V. Schally

Andrew V. Schally, Ph.D., M.D.h.c., received his training in England, Canada, Sweden, and USA. In the years 1954-1977 he worked in the field of neuroendocrinology. Dr. Schally’s group isolated and elucidated the structure of hypothalamic LHRH. Dr. Schally was awarded the Nobel Prize in Medicine in 1977 for his work on hypothalamic peptides. Dr. Schally switched then to cancer research. He is a world leader in research on hormone-related cancers and treatment of prostate and other cancers. Various classes of anticancer peptides were developed in his laboratory. Dr. Schally is the Professor of Pathology and Medicine at the University of Miami School of Medicine, Chief of the Endocrine, Polypeptide Cancer Institute at the VA Medical Center, Miami, Florida and Distinguished Medical Research Scientist. He has more than 2500 publications to his credit.

)

(Nobel Laureate)
VAMC
New Orleans, LA
USA

Nese Tuncel (Biography
Nese Tuncel

Dr. Neşe Tunçel received her BS in Pharmacy in 1970 and her PhD in Medical Physiology in 1982 from Ankara University, Turkey. She has been served as a Professor in the Department of Physiology and Neurophysiology, Faculty of Medicine, Eskis􏰁ehir Osmangazi University, and she was retired in April 2016. She has 95 scientific publications. She also serves as a member of the Editorial boards of several academic journals including Current Pharmaceutical Design, Medicinal Chemistry, Recent Patents on Anti-Cancer Drug Discovery, The Open Cancer Journal, Biomedical Review and Adipobiology, Current Clinical pharmacology. She has also served in the Editorial Advisory Board of Peptides in the period 1998-2010 and, Immunology, Endocrine and Metabolic Agents for three years.

)

Osmangazi University
Eskisehir
Turkey

Yuri V. Bobryshev (Biography
Yuri V. Bobryshev

Prof. Bobryshev obtained a doctorate (Dr.Sc.) from the Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences. Currently Dr Bobryshev is a Senior Research Associate of the Faculty of Medicine, University of New South Wales, Sydney, Australia and Adjunct Associate Professor of the School of Medicine, University of Western Sydney, Australia. Dr Bobryshev is a Fellow of Faculty of Science of the Royal College of Pathologists of Australasia (RCPA). Dr Bobryshev has published more than 300 scientific publications.

)

University of New South Wales
Sydney
Australia

Elisabeth G.E. De Vries
Univ. of Groningen
Groningen
Netherlands

Catherine L. Farrell
Amgen, Inc., Thousand Oaks
CA
USA

Tingjun Hou (Biography
Tingjun Hou

Dr. Hou obtained a doctorate (Ph.D.) in Computational Chemistry from Peking University in 2002 and is currently the professor for College of Pharmaceutical Sciences at Zhejiang University in Hangzhou. His research focuses on development of new methods for computer-aided drug design (CADD) and design of potential lead compounds for important drug targets. He has published more than 260 peer reviewed papers in international prestigious SCI-cited journals, 4 book chapters and 1 multimedia courseware.

)

Soochow University
Suzhou, Jiangsu
China

Kit S. Lam
UC Davis Cancer Center
Sacramento, CA
USA

John H. Musser
Glycomed
Alameda, CA
USA

Manfredi Rizzo (Biography
Manfredi Rizzo

Prof. Rizzo is Associate Professor of Internal Medicine at the School of Medicine, University of Palermo, Italy as well as Associate Professor of Internal Medicine at the School of Medicine, University of South Carolina, USA. Prof. Rizzo sits on the editorial board of 9 international journals with Impact Factor. He has been the recipient of national and international fellowships and awards, and acted as reviewer for 100+ scientific international journals. The research work of Dr. Rizzo combines translational research (focus on the effects and mechanisms of action of lipid-lowering and anti‐diabetic agents) and basic research (focus on novel cardiovascular risk factors), with 200+ scientific publications with Impact Factor (total Impact Factor: >700. H‐Index: 42).

)

University of Palermo
Palermo
Italy

Claudio Soto (Biography
Claudio Soto

Dr Claudio Soto is Professor of Neurology and Director of the Mitchell Center for Alzheimer’s disease and related Brain Disorders at the University of Texas in Houston. He received his PhD from the University of Chile in 1993. His research focuses in understanding the molecular basis of neurodegenerative diseases associated to the misfolding and aggregation of proteins, particularly Alzheimer’s and prion disorders. He has published more than 160 peer review articles, many of which have been published in prestigious scientific journals (including Cell, Nature, Science, New England Journal of Medicine, Nature medicine, Lancet, etc). Dr Soto's publications have been cited more than 12,000 times (H index 59). He has been awarded many grants from NIH, and private foundations for a total funding of over 30 million dollars, and has been invited speaker in more than 160 scientific meetings worldwide.

)

University of Texas Medical Branch
Galveston, TX
USA

Antonino Tuttolomondo
Università degli Studi di Palermo
Palermo
Italy


Executive Guest Editor(s):

Asfar Azmi
(USA)

Issue Title: Systems and Network Biology in Pharmaceutical Drug Discovery



Stefan Barth
(Germany)

Issue Title: The snap-tag technology - a versatile biotechnological tool for different applications



Matthias Barton
(Switzerland)

Issue Title: The G Protein-Coupled Estrogen Receptor: Molecular Pharmacology and Therapeutic Targets



Angus Bell
(Ireland)

Issue Title: Anti-malarial Drug Discovery and Design in the Era of Resistance



Jerzy Beltowski
(Poland)

Issue Title: Leptin as a Therapeutic Target in Cardiovascular Diseases



Pier Giuseppe de Benedetti
(Italy)

Issue Title: Protonation states & conformational dynamics in ligand-target recognition & binding



Sagnik Bhattacharyya
(UK)

Issue Title: Neurobiological and Neurocognitive Basis of The Effects of Cannabinoids In Animals and Man: Therapeutic Potential of Cannabinoids In Psychiatry



Yuri Bobryshev
(Australia)

Issue Title: Novel targets and biomarkers for anti-atherosclerotic therapy



Elena Chiarpotto
(Italy)

Issue Title: Antioxidants in lifestyle and therapeutics of the elderly



Chi Cho
(China)

Issue Title: miRNA in the pathogenesis and therapy for gastrointestinal and hepatic cancers



Van Christophe
(Belgium)

Issue Title: Radiolabbeled imaging probes for personalized imaging



Paul Christou
(Spain)

Issue Title: From medicinal plants to medicines in plants: A paradigm shift in using plants as factories for the production of valuable pharmaceuticals



Alberto Del Rio
(Italy)

Issue Title: Epigenetics and metabolic drug target for anticancer therapy



Antonio Espuny
(USA)

Issue Title: Advances in the treatment of neurodegenerative diseases and epilepsy



Matilda Florentin
(Greece)

Issue Title: Achieving Current Goals in Prevention and Treatment of Vascular Disease: an update



Armen Gasparyan
(UK)

Issue Title: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design



Víctor González
(Spain)

Issue Title: New insights in the insulin resistance, cardiovascular diseases and oxidative stress: pathophysiological and clinical consequences



Ioanna Gouni-Berthold
(Germany)

Issue Title: Current and future options for lipid-lowering therapy beyond statins



Maria Teresa Valero Griñán
(Greece)

Issue Title: Mitochondrial Biogenesis: Pharmacological Approaches



Pierre Guertin
(Canada)

Issue Title: Pharmacology and Biochemistry of Stereotyped Motor Behaviors



Twanda Gumbo
(USA)

Issue Title: Design of optimized anti-TB drug regimens with keys from evolution and biological variability



Nancy Hanson
(USA)

Issue Title: Resistance in Gram-negative Pathogens: A Threat to Global Health



Phillip Harrison
(UK)

Issue Title: Hepatitis Delta: Epidemiology, Pathogenesis and Therapy



Mamoru Isemura
(Japan)

Issue Title: Plant Polyphenols and Health Benefits



Hani Jneid
(USA)

Issue Title: Updates in the Management of Acute Coronary Syndromes



Hiroyuki Kinoshita
(Japan)

Issue Title: Roles of anesthetics and opioids in organ or tissue protection



Theofilos Kolettis
(Greece)

Issue Title: Novel strategies for cardiac repair post-myocardial infarction



Cato Laurencin
(USA)

Issue Title: Bone Morphogenetic Proteins (BMPs) for Bone Regeneration and their alternatives



Fulvio Lauretani
(Italy)

Issue Title: The multidomain mobility lab in older persons: from bench to bedside



Bernard Lebleu
(France)

Issue Title: Cell penetrating peptides as delivery vectors for biomolecules



Aurelio Leone
(Italy)

Issue Title: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage



Adam Lesner
(Poland)

Issue Title: Proteolysis and its control in health and disease



Huige Li
(Denmark)

Issue Title: Therapeutic strategies to target endothelial nitric oxide synthase (eNOS)



Guang Liang
(China)

Issue Title: Drug Development Based on the Structure and Multiple Pharmacological Targets of Curcumin



Giovanni Li Volti
(Italy)

Issue Title: Pharmacological and molecular targets in cellular redox status maintenance



Carla Lopes
(Portugal)

Issue Title: Therapeutic Applications of Advanced Drug Delivery Systems



Buyong Ma
(USA)

Issue Title: Protein-protein interaction: from interface to interaction network



Emilio Jirillo
(Italy)

Issue Title: Plant-derived foods for the attenuation of allergic airway inflammation



Thea Magrone
(Italy)

Issue Title: Therapeutics targeting the ubiquitin-proteasome system: current status and prospective



Xinliang Mao
(China)

Issue Title: Therapeutics targeting the ubiquitin-proteasome system: current status and prospective



Milagros Medina
(Spain)

Issue Title: Flavoproteins and Flavoenzymes with Biomedical and Therapeutic Impact



Dimitri Mikhailidis
(UK)

Issue Title: New Developments in the Prevention and Treatment of Vascular Disease – 3 Diabetes, obesity and vascular disease – an update



Michele Milella
(Italy)

Issue Title: The Lung and winding road: twists and turns on the way to personalized NSCLC therapy



Shin-ichrio Miura
(Japan)

Issue Title: Angiotensin II Receptors Research



Eugenio Mocchegiani
(Italy)

Issue Title: Cellular Senescence: Advances and Therapeutic Targets in Aging and Major Age-Related Diseases



Stefano Moro
(Italy)

Issue Title: In silico approaches in G protein-coupled receptors (GPCRs) drug discovery: quo vadis?



Jordi Muntané
(Spain)

Issue Title: Targeting Cell death and proliferation receptors in cancer



Rami Mutyala
(USA)

Issue Title: Rational Drug Design



Hitoshi Nakamoto
(Japan)

Issue Title: Molecular chaperones as drug targets



Péter P Nánási
(Hungary)

Issue Title: Perspectives of antiarrhythmic therapy: new trails, challenges and pitfalls



Silvio Naviglio
(Italy)

Issue Title: Naturally occurring molecules and anticancer combination therapies in the era of personalized medicine and economic crisis



Joseph Ndisang
(Canada)

Issue Title: Cardio-metabolic complications: current perspective and future developments



Erika Nieddu
(Italy)

Issue Title: Cystic Fibrosis: CFTR modulators and their mechanism of action



Robert Nistico
(Italy)

Issue Title: Targeting synaptic dysfunction and neural connectivity in neurological and psychiatric disorders



Jose Orriach
(Spain)

Issue Title: Current perioperative therapy for patients with cardiovascular disease: addressing the new and optimizing the old



Angel Pazos
(Spain)

Issue Title: Future trends in the development of new antidepressant drugs



Carmen Peralta
(Spain)

Issue Title: Therapeutic targets and pharmacological strategies in steatotic and non-steatotic liver transplantation



Paola Perego
(Italy)

Issue Title: The Ubiquitin Proteasome System as a source of drug targets for cancer therapy



Susanne Perkhofer
(Austria)

Issue Title: Invasive Aspergillosis: new insights into disease, diagnostic and treatment



Godefridus Peters
(Netherlands)

Issue Title: Development of new molecular agents targeting key signalling pathways activated by growth factors in human cancer



Salvatore Petta
(Italy)

Issue Title: Update on Treatment Strategies in Patients with Non-alcoholic Fatty Liver Disease



Italo Porto
(Italy)

Issue Title: Pharmacological Prevention and Therapy of No Reflow in the Catheterization Laboratory: New Insights from Basic and Clinical Science



Jun Ren
(USA)

Issue Title: Pathophysiology And Therapeutics of Cardiovascular Health in Metabolic Syndrome



Manfredi Rizzo
(Italy)

Issue Title: Novel therapeutic targets in the Metabolic Syndrome



Marta Rodriguez-Arias
(Spain)

Issue Title: Cocaine and amphetamine-type stimulants: the search for pharmacological therapies



Patrick Ronaldson
(USA)

Issue Title: Targeting Transporters for CNS Drug Delivery



Patrizia Russo
(Italy)

Issue Title: Disease control and Active and Healthy Ageing: new paradigms of therapeutic strategy



Marcos Santos
(Brazil)

Issue Title: Parasite Polyamines as Pharmaceutical Targets



Helmut Schmidhammer
(Austria)

Issue Title: Current Perspectives and Challenges in Design, Chemistry and Pharmacology of Opioids



Predrag Sikiric
(Croatia)

Issue Title: From gut inflammation to gastrointestinal disorders Current update on pathophysiology, molecular mechanism and pharmacological treatment modalities



Andreas Stengel
(Germany)

Issue Title: New developments on NUCB2/nesfatin-1



JianJun Tan
(China)

Issue Title: The discovery of novel inhibitors for the treatment of HIV infection



Gian Mario Tiboni
(Italy)

Issue Title: Advances in Developmental and Reproductive Toxicology



Andrea Tinelli
(Italy)

Issue Title: Exploring molecular and clinical management of patients in the follow up of the hpv related uterine lesions



Antonio Toninello
(Italy)

Issue Title: Mitochondria and subcellular organelles as treatment target against pathological conditions



Miguel Torres
(Spain)

Issue Title: Targeting the Metabolism of Cancer Cells



Dimitris Tousoulis
(Greece)

Issue Title: Stable angina pectoris: novel therapeutic insights



Luigia Trabace
(Italy)

Issue Title: Soluble beta amyloid in a continuum from physiology to pathology: searching the determinants of its effects and designing new pharmacological treatments



Bruno Tuttolomondo
(Italy)

Issue Title: Anderson Fabry disease : A multiorgan metabolic disease susceptible of treatment



John van den Anker
(USA)

Issue Title: Neonatal and Pediatric Clinical Pharmacology



Zhi Xu
(Australia)

Issue Title: Nanotechnology in Pharmaceutical Design



Sho-ichi Yamagishi
(Japan)

Issue Title: Novel therapeutic targets for cardiovascular disease



Bing Yan
(USA)

Issue Title: Therapy at the Nano Dimension



Xinhua Yan
(USA)

Issue Title: Targeting Neuregulin1 and ErbB2 for Therapy of Breast Cancer and Heart Failure



Yongliang Yang
(China)

Issue Title: Rational Drug Design with the Aid of Molecular Modeling and Bioinformatics



Weihai Ying
(China)

Issue Title: Mechanisms and Therapeutic Strategies for Ischemic Brain Injury: Current Advances and Future Perspectives



Zheng Ying
(Macau)

Issue Title: Novel Formulation Strategies for Poorly Water-soluble Drugs and Herbal Medicines



Jinchao Zhang
(China)

Issue Title: Recent Progress and Future Potential for Metal-Based Drugs



Junnian Zheng
(China)

Issue Title: MicroRNA-regulated replication specificity of oncolytic virotherapy for cancer



Min Zhuo
(Canada)

Issue Title: Molecular understanding of pain and future treatment of chronic pain





Advertisement
4th Microbiome R&D and Business Collaboration Forum: EuropeRNA Therapeutics 2017

Related Journals




Related eBooks


Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science